IBJNews

Study: Arthritis drug co-developed by Lilly shows promise

Back to TopCommentsE-mailPrintBookmark and Share

Incyte Corp. says a study of an experimental pill developed with Eli Lilly and Co. for rheumatoid arthritis showed the drug reduces inflammation in patients’ joints at all doses.

At the highest dose of 10 milligrams, 72 percent of patients taking the drug daily had a 20-percent reduction in joint swelling after 24 weeks, 44 percent had a 50-percent drop and 28 percent had a 70-percent decline, Wilmington, Del.-based Incyte said in a prepared statement. By comparison, 32 percent of patients taking placebos had a 20-percent drop in inflammation, 13 percent had a 50-percent decline and 3 percent had a 70-percent drop, the company said.

The drug, previously known as INCB28050, will be called LY3009104, and Indianapolis-based Lilly will be responsible for future clinical trials, Incyte said in its statement. Headache, upper respiratory tract infections, and diarrhea were the most frequently reported side effects mentioned by the 125 patients who took part in the study, the company said.

Lilly paid $90 million in 2009 to acquire the global rights to the treatment in a bid to beef up its pipeline of medications for autoimmune diseases. If the drug makes it to market, Lilly could pay another $665 million to Incyte for reaching various milestones along the way.

The latest study results suggest that “the compound has the potential to become a welcome addition” to current therapies, said Maria Greenwald, a Palm Desert, Calif., rheumatologist who led the study. The findings were released Thursday at the American College of Rheumatology meeting in Atlanta.

In rheumatoid arthritis, the body’s immune system attacks itself, causing joint inflammation and swelling that can lead to progressive destruction of the joints. The disease affects about 1 percent of the world’s population.

The pill is one of a family of experimental treatments for rheumatoid arthritis targeting a protein called JAK that leads to joint destruction. Pfizer Inc. also reported results showing an experimental JAK-targeted medicine that reduced pain and inflammation in a trial released at the rheumatology meeting.

Three biotechnology companies are developing JAK drugs: Incyte, Rigel Pharmaceuticals Inc. of San Francisco, Calif., and Cambridge, Mass.-based Vertex Pharmaceuticals Inc.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. These liberals are out of control. They want to drive our economy into the ground and double and triple our electric bills. Sierra Club, stay out of Indy!

  2. These activist liberal judges have gotten out of control. Thankfully we have a sensible supreme court that overturns their absurd rulings!

  3. Maybe they shouldn't be throwing money at the IRL or whatever they call it now. Probably should save that money for actual operations.

  4. For you central Indiana folks that don't know what a good pizza is, Aurelio's will take care of that. There are some good pizza places in central Indiana but nothing like this!!!

  5. I am troubled with this whole string of comments as I am not sure anyone pointed out that many of the "high paying" positions have been eliminated identified by asterisks as of fiscal year 2012. That indicates to me that the hospitals are making responsible yet difficult decisions and eliminating heavy paying positions. To make this more problematic, we have created a society of "entitlement" where individuals believe they should receive free services at no cost to them. I have yet to get a house repair done at no cost nor have I taken my car that is out of warranty for repair for free repair expecting the government to pay for it even though it is the second largest investment one makes in their life besides purchasing a home. Yet, we continue to hear verbal and aggressive abuse from the consumer who expects free services and have to reward them as a result of HCAHPS surveys which we have no influence over as it is 3rd party required by CMS. Peel the onion and get to the root of the problem...you will find that society has created the problem and our current political landscape and not the people who were fortunate to lead healthcare in the right direction before becoming distorted. As a side note, I had a friend sit in an ED in Canada for nearly two days prior to being evaluated and then finally...3 months later got a CT of the head. You pay for what you get...

ADVERTISEMENT